In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts

Devin R. Mccormack, Alex J. Walsh, Wesley Sit, Carlos L. Arteaga, Jin Chen, Rebecca S. Cook, Melissa C. Skala

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

HER2-amplified (HER2 +) breast cancers are treated with the anti-HER2 monoclonal antibody trastuzumab. Although trastuzumab reduces production of the angiogenic factor VEGF in HER2 + tumors, the acute and sustained effects of trastuzumab on the tumor vasculature are not understood fully, particularly in trastuzumab-resistant tumors. We used mouse models of trastuzumab sensitive and trastuzumab-resistant HER2 + breast cancers to measure dynamic changes in tumor microvessel density and hemoglobin oxygenation (sO2) in vivo using quantitative hyperspectral imaging at 2, 5, 9, and 14 days after antibody treatment. Further analysis quantified the distribution of microvessels into low and high oxygenation groups, and monitored changes in these distributions with trastuzumab treatment. Gold standard immunohistochemistry was performed to validate complementary markers of tumor cell and vascular response to treatment. Trastuzumab treatment in both responsive and resistant tumors resulted in decreased sO2 5 days after initial treatment when compared to IgG-treated controls (p<0.05). Importantly, responsive tumors showed significantly higher vessel density and significantly lower sO2 than all other groups at 5 days post-treatment (p<0.05). Distribution analysis of vessel sO2 showed a significant (p<0.05) shift of highly oxygenated vessels towards lower oxygenation over the time-course in both trastuzumab-treated responsive and resistant tumors. This study suggests that longitudinal hyperspectral imaging of microvessel sO2 and density could distinguish trastuzumab responsive from trastuzumab-resistant tumors, a finding that could be exploited in the post-neoadjuvant setting to guide post-surgical treatment decisions.

Original languageEnglish (US)
Pages (from-to)2247-2261
Number of pages15
JournalBiomedical Optics Express
Volume5
Issue number7
DOIs
StatePublished - Jun 1 2014

Fingerprint

Microvessels
Heterografts
breast
tumors
cancer
Breast Neoplasms
oxygenation
Neoplasms
vessels
Therapeutics
antibodies
Trastuzumab
hemoglobin
markers
Angiogenesis Inducing Agents
mice
Tumor Biomarkers
Vascular Endothelial Growth Factor A
Blood Vessels
Longitudinal Studies

ASJC Scopus subject areas

  • Biotechnology
  • Atomic and Molecular Physics, and Optics

Cite this

In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts. / Mccormack, Devin R.; Walsh, Alex J.; Sit, Wesley; Arteaga, Carlos L.; Chen, Jin; Cook, Rebecca S.; Skala, Melissa C.

In: Biomedical Optics Express, Vol. 5, No. 7, 01.06.2014, p. 2247-2261.

Research output: Contribution to journalArticle

Mccormack, Devin R. ; Walsh, Alex J. ; Sit, Wesley ; Arteaga, Carlos L. ; Chen, Jin ; Cook, Rebecca S. ; Skala, Melissa C. / In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts. In: Biomedical Optics Express. 2014 ; Vol. 5, No. 7. pp. 2247-2261.
@article{d728f744a4b3433c8d5b3ed78b45f407,
title = "In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts",
abstract = "HER2-amplified (HER2 +) breast cancers are treated with the anti-HER2 monoclonal antibody trastuzumab. Although trastuzumab reduces production of the angiogenic factor VEGF in HER2 + tumors, the acute and sustained effects of trastuzumab on the tumor vasculature are not understood fully, particularly in trastuzumab-resistant tumors. We used mouse models of trastuzumab sensitive and trastuzumab-resistant HER2 + breast cancers to measure dynamic changes in tumor microvessel density and hemoglobin oxygenation (sO2) in vivo using quantitative hyperspectral imaging at 2, 5, 9, and 14 days after antibody treatment. Further analysis quantified the distribution of microvessels into low and high oxygenation groups, and monitored changes in these distributions with trastuzumab treatment. Gold standard immunohistochemistry was performed to validate complementary markers of tumor cell and vascular response to treatment. Trastuzumab treatment in both responsive and resistant tumors resulted in decreased sO2 5 days after initial treatment when compared to IgG-treated controls (p<0.05). Importantly, responsive tumors showed significantly higher vessel density and significantly lower sO2 than all other groups at 5 days post-treatment (p<0.05). Distribution analysis of vessel sO2 showed a significant (p<0.05) shift of highly oxygenated vessels towards lower oxygenation over the time-course in both trastuzumab-treated responsive and resistant tumors. This study suggests that longitudinal hyperspectral imaging of microvessel sO2 and density could distinguish trastuzumab responsive from trastuzumab-resistant tumors, a finding that could be exploited in the post-neoadjuvant setting to guide post-surgical treatment decisions.",
author = "Mccormack, {Devin R.} and Walsh, {Alex J.} and Wesley Sit and Arteaga, {Carlos L.} and Jin Chen and Cook, {Rebecca S.} and Skala, {Melissa C.}",
year = "2014",
month = "6",
day = "1",
doi = "10.1364/BOE.5.002247",
language = "English (US)",
volume = "5",
pages = "2247--2261",
journal = "Biomedical Optics Express",
issn = "2156-7085",
publisher = "The Optical Society",
number = "7",

}

TY - JOUR

T1 - In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts

AU - Mccormack, Devin R.

AU - Walsh, Alex J.

AU - Sit, Wesley

AU - Arteaga, Carlos L.

AU - Chen, Jin

AU - Cook, Rebecca S.

AU - Skala, Melissa C.

PY - 2014/6/1

Y1 - 2014/6/1

N2 - HER2-amplified (HER2 +) breast cancers are treated with the anti-HER2 monoclonal antibody trastuzumab. Although trastuzumab reduces production of the angiogenic factor VEGF in HER2 + tumors, the acute and sustained effects of trastuzumab on the tumor vasculature are not understood fully, particularly in trastuzumab-resistant tumors. We used mouse models of trastuzumab sensitive and trastuzumab-resistant HER2 + breast cancers to measure dynamic changes in tumor microvessel density and hemoglobin oxygenation (sO2) in vivo using quantitative hyperspectral imaging at 2, 5, 9, and 14 days after antibody treatment. Further analysis quantified the distribution of microvessels into low and high oxygenation groups, and monitored changes in these distributions with trastuzumab treatment. Gold standard immunohistochemistry was performed to validate complementary markers of tumor cell and vascular response to treatment. Trastuzumab treatment in both responsive and resistant tumors resulted in decreased sO2 5 days after initial treatment when compared to IgG-treated controls (p<0.05). Importantly, responsive tumors showed significantly higher vessel density and significantly lower sO2 than all other groups at 5 days post-treatment (p<0.05). Distribution analysis of vessel sO2 showed a significant (p<0.05) shift of highly oxygenated vessels towards lower oxygenation over the time-course in both trastuzumab-treated responsive and resistant tumors. This study suggests that longitudinal hyperspectral imaging of microvessel sO2 and density could distinguish trastuzumab responsive from trastuzumab-resistant tumors, a finding that could be exploited in the post-neoadjuvant setting to guide post-surgical treatment decisions.

AB - HER2-amplified (HER2 +) breast cancers are treated with the anti-HER2 monoclonal antibody trastuzumab. Although trastuzumab reduces production of the angiogenic factor VEGF in HER2 + tumors, the acute and sustained effects of trastuzumab on the tumor vasculature are not understood fully, particularly in trastuzumab-resistant tumors. We used mouse models of trastuzumab sensitive and trastuzumab-resistant HER2 + breast cancers to measure dynamic changes in tumor microvessel density and hemoglobin oxygenation (sO2) in vivo using quantitative hyperspectral imaging at 2, 5, 9, and 14 days after antibody treatment. Further analysis quantified the distribution of microvessels into low and high oxygenation groups, and monitored changes in these distributions with trastuzumab treatment. Gold standard immunohistochemistry was performed to validate complementary markers of tumor cell and vascular response to treatment. Trastuzumab treatment in both responsive and resistant tumors resulted in decreased sO2 5 days after initial treatment when compared to IgG-treated controls (p<0.05). Importantly, responsive tumors showed significantly higher vessel density and significantly lower sO2 than all other groups at 5 days post-treatment (p<0.05). Distribution analysis of vessel sO2 showed a significant (p<0.05) shift of highly oxygenated vessels towards lower oxygenation over the time-course in both trastuzumab-treated responsive and resistant tumors. This study suggests that longitudinal hyperspectral imaging of microvessel sO2 and density could distinguish trastuzumab responsive from trastuzumab-resistant tumors, a finding that could be exploited in the post-neoadjuvant setting to guide post-surgical treatment decisions.

UR - http://www.scopus.com/inward/record.url?scp=84903709007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903709007&partnerID=8YFLogxK

U2 - 10.1364/BOE.5.002247

DO - 10.1364/BOE.5.002247

M3 - Article

C2 - 25071962

AN - SCOPUS:84903709007

VL - 5

SP - 2247

EP - 2261

JO - Biomedical Optics Express

JF - Biomedical Optics Express

SN - 2156-7085

IS - 7

ER -